|
Summary:
Tercica is a late-stage biopharmaceutical company focused on the development and commercialization of therapies to treat endocrine disorders, including human growth and diabetes. Tercica’s lead product is Increlex®, which is a long-term replacement therapy for the treatment of short stature in children with severe primary insulin-like growth factor-1 deficiency, or severe Primary IGFD, and for children with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone.
Tercica Case Study
|
